Vaccine-driven immunity is a multifaceted puzzle. The focus on designing antigens stems from our evolving comprehension of how they trigger diverse immune responses. Moreover, the rapid rise of messenger RNA (mRNA) vaccines, built on groundbreaking mRNA technology, has ushered in new possibilities for treating conditions like cancer and infectious diseases.
Vaccines encompass diverse modalities, incorporating live attenuated or inactivated organisms, as well as formulations derived from partially purified components. The forefront of vaccine innovation now involves the development of RNA and DNA vaccines, representing the latest strides in harnessing genetic material to induce targeted immune responses.
Whether your vaccine development journey involves bacterial, viral, or nucleic acid molecules, we provide the tools to improve yields, lower costs, ensure quality, and cut down your manufacturing process.
Selection of antigens for vaccine development requires identifying and preparing specific molecules that mimic the target pathogen to trigger a protective immune response.
Separating antigens from impurities is a pivotal step, safeguarding the purity and safety of the ultimate vaccine formulation.
Vaccine formulation directly impacts the product's safety, efficacy, and stability to ensure that it can effectively protect against the targeted disease.
Monitoring product integrity, especially protein aggregation during formulation, facilitates the refinement of manufacturing processes to maintain strict regulatory standards protective immunity.
Monitoring the immune response to the introduction of antigen allows to assess the effectiveness of vaccines and tailor strategies for enhancing protective immunity.
Generating and validating antigens for vaccine development requires selecting and preparing specific molecules that mimic the target pathogen to trigger a protective immune response.
Enzo offers various native-state bacterial and viral antigens for vaccine research. These are native or recombinant proteins produced in the latest expression systems to ensure high-level expression, maintenance of their native-folded state, and retention of all relevant post-translational modifications (PTM).
Pertussis Toxin
A model is built using data of molecular structure from CPs Undetected HCPs Protein Data Bank (PDB 1PRT)
The challenge in vaccine manufacturing lies in effectively monitoring and managing contamination. Separating antigens from impurities is a pivotal step, safeguarding the purity and safety of the ultimate vaccine formulation.
Enzo offers Host Cell Protein (HCP) ELISA kits and reagents for contamination monitoring that are ideal for impurity analysis.
Related Products
CHO HCP Standards
CHO HCP polyclonal antibody
CHO HCP polyclonal antibody (biotin conj)
E.coli HCP Standards
E.coli HCP polyclonal antibody
E.coli HCP polyclonal antibody (biotin conj)
HEK293T Host Cell Protein Standard
Monitor CHO HCP Residuals with Confidence
CHO Host Cell ELISA Protein Kit was compared to the leading competitor's kit. Results indicate that Enzo's ELISA kit has 25% more coverage than the leading competitor's kit
A robust and targeted immune response is essential for the vaccine to provide protection against the targeted disease.
We offer a comprehensive portfolio of products that enhance the magnitude and durability of the vaccine immune response, including MEGACD40L® Protein. CD40 ligand (CD40L) plays a central role in co-stimulation and regulation of the immune response.
MEGACD40L® Protein is a highly active and pure CD40L recombinant protein that can enhance an immune response without additional enhancers.
Related Products
Monophosphoryl Lipid A (synthetic)
MALP-2
Polyinosinic-polycytidylic acid . potassium salt (TLRGRADE®) (synthetic)
Paclitaxel
R-848
ODN 2006 (TLRGRADE®) (synthetic)
ODN 1826 (TLRGRADE®) (synthetic)
Improved Stability and Enhanced Activity Compared to CD40L and CD40L with enhancers
B cell lymphocyte activation by various CD40L constructs. PBMCs were treated for 48 hours in media containing serially diluted CD40L, CD40L + 2 μg/mL Enhancer, or MEGACD40L® Protein. Cells were dual-stained with α-human CD19–PE and α-human CD86–APC and analyzed by flow cytometry. Data are presented as the percent of CD19+ B cells that co-stain as CD86+.
Aggregation poses a substantial challenge in vaccine manufacturing. It can impact product quality, safety, and efficacy. Ensuring structural integrity, preventing safety concerns, and optimizing production processes are critical to meeting regulatory standards and ensuring vaccine stability and efficacy.
Product stability can be assessed by monitoring protein aggregation with PROTEOSTAT® Protein Aggregation Assay, allowing the optimization, formulation, and manufacturing processes.
Related Products
PROTEOSTAT® Protein Aggregation Standards
PROTEOSTAT® Protein Refolding and Aggregation sensing kit
PROTEOSTAT® Thermal Shift Stabillity Assay Kit
PROTEOSTAT® Aggresome Assay
PROTEOSTAT® Dye Yields Much Brighter Signal
Signal intensity of PROTEOSTAT® aggregate sensing dye compared other dyes
Assessing the vaccine's effectiveness by monitoring the immune response when the antigen is introduced is crucial to tailor strategies to enhance protective immunity.
Measuring IL-6 levels in response to vaccination can provide insights into the vaccine's immunostimulatory effects. Enzo offers one of the most sensitive IL-6 ELISA Kits on the market.
Related Products
IFN-γ (human), ELISA kit
IL-8 (human), ELISA kit
IL-1β (human), ELISA kit
TNF-α (human), ELISA kit
IL-10 (human), ELISA kit
cAMP complete ELISA kit
PGE2 high sensitivity ELISA kit
Detect IL-6 in Several Sample Types
Parallelism curve for IL-6 (human), high sensitivity ELISA kit
Antibodies are indispensable tools in vaccine research, from initial antigen discovery to vaccine design, efficacy testing, manufacturing, and quality control. They are fundamental in understanding and harnessing the immune response to develop safe and effective vaccines.
LAG-3 is used as a marker in immune monitoring and assessment of vaccine-induced immune responses. Measuring LAG-3 expression on T cells provides insights into the immune system's status and its potential to respond to vaccination.
Detection of LAG-3 in Human Tonsil Tissue
Immunohistochemistry analysis of human tonsil tissue (60x) using LAG-3 (human) recombinant mAb (L4-PL33), at a dilution of 1:50
Leverage over 45 years of innovation and technical expertise supporting drug development, discovery, research, and diagnostics through our core technology platforms. With over 150,000 citations, GMP and ISO certifications, our highly-sensitive, quality products consistently deliver trusted results. We maintain product integrity and reliability with our in-house U.S. manufacturing facility. We deploy our bench of expert PhD scientists to provide technical, tailored, support for our customers and their projects.
Rely on our extensive experience in innovation, technology development, and manufacturing to support your vaccine research and development. Our comprehensive Life Sciences Contract Services support the development of customizable, unique, and efficient solutions for all your research needs.
